Cargando…

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

Mucosal antibodies harboring various antiviral activities may best protect mucosal surfaces against early HIV-1 entry at mucosal sites and they should be ideally induced by prophylactic HIV-1 vaccines for optimal prevention of sexually transmitted HIV-1. A phase I, double-blind, randomized, placebo-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leroux-Roels, Geert, Maes, Cathy, Clement, Frédéric, van Engelenburg, Frank, van den Dobbelsteen, Marieke, Adler, Michael, Amacker, Mario, Lopalco, Lucia, Bomsel, Morgane, Chalifour, Anick, Fleury, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577797/ https://www.ncbi.nlm.nih.gov/pubmed/23437055 http://dx.doi.org/10.1371/journal.pone.0055438

Ejemplares similares

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes
por: Amacker, Mario, et al.
Publicado: (2020)

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis
por: Duchemin, Maxence, et al.
Publicado: (2018)

The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity
por: Xu, Lin, et al.
Publicado: (2021)

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2023)

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
por: Tamborrini, Marco, et al.
Publicado: (2011)

Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41
por: Duchemin, Maxence, et al.
Publicado: (2020)

Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models
por: Tamborrini, Marco, et al.
Publicado: (2020)

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination
por: Bomsel, Morgane, et al.
Publicado: (2023)

Peptide P5 (residues 628–683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection
por: Yu, Huifeng, et al.
Publicado: (2008)

Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate
por: Fernandes, Bárbara, et al.
Publicado: (2022)

The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals
por: Khamassi, Marwa, et al.
Publicado: (2020)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

A Triple Co-Culture Model of the Human Respiratory Tract to Study Immune-Modulatory Effects of Liposomes and Virosomes
por: Blom, Rebecca A. M., et al.
Publicado: (2016)

Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate
por: Fernandes, Bárbara, et al.
Publicado: (2022)

Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4(+) T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen
por: Blom, Rebecca A. M., et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Virosome: An engineered virus for vaccine delivery
por: Ali, Hasan, et al.
Publicado: (2023)

Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice
por: Kamphuis, Tobias, et al.
Publicado: (2012)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults
por: Leroux-Roels, Isabel, et al.
Publicado: (2020)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
por: Lakhashe, Samir K., et al.
Publicado: (2022)

Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
por: Benen, Thomas D, et al.
Publicado: (2014)

A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge
por: Koopman, Gerrit, et al.
Publicado: (2023)

Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial
por: Leroux-Roels, Geert, et al.
Publicado: (2020)

Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: A double-blind randomized trial
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

Influenza T-cell Epitope-Loaded Virosomes Adjuvanted with CpG as a Potential Influenza Vaccine
por: Soema, Peter C., et al.
Publicado: (2014)

Virosome Presents Multimodel Cancer Therapy without Viral Replication
por: Saga, Kotaro, et al.
Publicado: (2013)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group
por: Vandoorn, Elien, et al.
Publicado: (2020)

Human Immunity and Susceptibility to Influenza A(H3) Viruses of Avian, Equine, and Swine Origin
por: Vandoorn, Elien, et al.
Publicado: (2023)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein
por: Vassell, Russell, et al.
Publicado: (2015)

Antiviral properties of two trimeric recombinant gp41 proteins
por: Delcroix-Genête, Delphine, et al.
Publicado: (2006)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity
por: Ajamian, Lara, et al.
Publicado: (2018)

HCV Animal Models: A Journey of More than 30 Years
por: Meuleman, Philip, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tt47es0adlj4op6v59piv2of1e